Why did FDA ask Amgen to add low-dose trial of Lumakras?

Researchers have expressed different opinions on why the U.S. FDA requested Amgen conduct a low-dose trial of Lumakras (sotorasib), the first Kras G12C inhibitor to treat cancer.

The latest issue of the Journal of Clinical Oncology (KCO), a journal by the American Society of Clinical Oncology (ASCO), published oncologists’ comments on the FDA’s approval condition for Lumakras.